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Abstract
Introduction: The lack of approved specific therapeutic agents to treat coronavirus
disease (COVID-19) associated with severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection has led to the rapid implementation of convalescent plasma
therapy (CPT) trials in many countries, including the United Kingdom. Effective CPT
Received: 17 August 2020 Revised: 30 September 2020 Accepted: 2 October 2020
DOI: 10.1111/tme.12746
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any
medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
© 2020 The Authors. Transfusion Medicine published by John Wiley & Sons Ltd on behalf of British Blood Transfusion Society.
Transfusion Medicine. 2020;1–9. wileyonlinelibrary.com/journal/tme 1
is likely to require high titres of neutralising antibody (nAb) in convalescent donations.
Understanding the relationship between functional neutralising antibodies and anti-
body levels to specific SARS-CoV-2 proteins in scalable assays will be crucial for the
success of a large-scale collection. We assessed whether neutralising antibody titres
correlated with reactivity in a range of enzyme-linked immunosorbent assays (ELISA)
targeting the spike (S) protein, the main target for human immune response.
Methods: Blood samples were collected from 52 individuals with a previous laboratory-
confirmed SARS-CoV-2 infection. These were assayed for SARS-CoV-2 nAbs by
microneutralisation and pseudo-type assays and for antibodies by four different ELISAs.
Receiver operating characteristic (ROC) analysis was used to further identify sensitivity
and specificity of selected assays to identify samples containing high nAb levels.
Results: All samples contained SARS-CoV-2 antibodies, whereas neutralising anti-
body titres of greater than 1:20 were detected in 43 samples (83% of those tested)
and >1:100 in 22 samples (42%). The best correlations were observed with
EUROimmun immunoglobulin G (IgG) reactivity (Spearman Rho correlation coefficient
0.88; p < 0.001). Based on ROC analysis, EUROimmun would detect 60% of samples
with titres of >1:100 with 100% specificity using a reactivity index of 9.1 (13/22).
Discussion: Robust associations between nAb titres and reactivity in several ELISA-
based antibody tests demonstrate their possible utility for scaled-up production of
convalescent plasma containing potentially therapeutic levels of anti-SARS-
CoV-2 nAbs.
K E YWORD S
convalescent plasma, COVID-19, neutralising antibody level, SARS-CoV-2, testing of plasma
1 | INTRODUCTION
The emergence of a novel coronavirus as a cause of respiratory dis-
ease occasionally leading to severe acute respiratory syndrome
(SARS) was first noted in the Hubei province, China in December
2019. From there, it rapidly spread to a number of countries, includ-
ing Italy, Iran, Spain and France.1 Subsequently, this virus was classi-
fied as SARS coronavirus 2 (SARS-CoV-2) within the genus
Betacoronavirus2 and its associated disease termed COVID-19. Mor-
tality due to COVID-19 is as high as 50% for patients admitted to
intensive care units.3
The first imported cases of SARS-CoV-2 were identified in the
United Kingdom at the end of January 2020, and local transmission
within the United Kingdom became evident 1 month later. As of 1st
May 2020, a total of 182 260 cases and 28 131 deaths have been
reported, and the numbers are predicted to continue to rise in this
first pandemic wave. Currently, there are no approved specific antivi-
rals targeting the novel virus, and convalescent plasma therapy (CPT)
has been suggested as an immediately available therapy. A systematic
review and retrospective meta-analysis, including 699 treated patients
with SARS-CoV-1 infection or severe influenza and 568 untreated
controls, demonstrated a statistically significant reduction in mortality
and in the pooled odds of mortality following treatment, compared
with placebo or no therapy (odds ratio 0.25; 95% CI: 0.14–0.45).4
Convalescent plasma may be an effective treatment for COVID-
19, with success linked to levels of neutralising antibody present in
plasma, which reduce viral replication and increase viral clearance.5,6
Virus-specific neutralising antibodies play a key role in viral clearance.
The spike (S) protein is responsible for the SARS-CoV-2 attachment
and entry to the target cells via the ACE-2 receptor, and neutralising
antibodies recognising the receptor-binding domain (RBD) on the S
protein have been shown to block viral entry.7 Antibodies against
other domains of S protein or possibly even against other proteins
may contribute to the functional neutralisation of the virus.
Neutralising antibodies are known to be detectable in patients
approximately 10–15 days after the onset of SARS-CoV-2 infection,8
but this antibody response continues to mature for at least 3 weeks9
and potentially longer.
The issue of the potential toxicity of convalescent plasma via
antibody-dependent enhancement (ADE) also needs to be
addressed carefully. It has been shown to occur when non-
neutralising or heterotypic antibodies facilitate viral entry into host
cells and enhance viral infectivity.10 It is likely to occur when anti-
body levels or specificities do not permit neutralisation.11 For these
reasons, it is important to determine neutralising antibody titres in
donated plasma, as well as a practical cut-off titre level, to evaluate
not only its safety but also its effectiveness for convalescent plasma
transfusion.
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Neutralising antibody levels can either be determined directly
using native or pseudo-type virus in cellular bioassays or be esti-
mated by ELISA if there is an adequate correlation between
neutralising antibody titre and ELISA reactivity. Neutralising anti-
body titre can be detected and quantified in a microneutralisation
assay format in which samples are assayed for their ability to block
infection of cells by SARS-CoV-2. Similarly, a pseudo-type assay can
be used to measure neutralising antibody levels using a virus con-
struct containing SARS-CoV-2 S protein in the surface of a lucifer-
ase tagged vesicular stomatitis virus or lentivirus viral vector.12,13
Both types of assays use suitably characterised target cells.
Although a limitation of microneutralisation assays using live virus is
the necessity to undertake work at biosafety level (BSL)-3 labora-
tory, a pseudo-type assay is more suitable for high-throughput
screening of convalescent plasma donors as it can be performed at a
BSL-2 facility.
In the current study, we have first determined the neutralising
antibody levels in our convalescent plasma donors and estimated a
cut-off to be used in clinical trials. Second, we have also assessed
whether there is a correlation between neutralisation antibody
titres (measured either using microneutralisation or pseudo-type
assay) and ELISA reactivity using a variety of assays formats includ-
ing cell lysate, in-house assays and two commercial ELISAs. Identi-
fication of a suitable high-throughput assay is required urgently to
support scaling up convalescent plasma production and to support
the comparison of data between countries.
2 | MATERIALS AND METHODS
2.1 | Convalescent plasma donors
We initiated the collection of convalescent plasma using the
established infrastructure and standard UK donor selection guidelines
during March 2020; serum and EDTA blood samples were collected
from individuals with a previous laboratory-confirmed SARS-CoV-2
infection at least 28 days after the resolution of their symptoms.
These donor samples were submitted to Public Health England and
tested initially for SARS-CoV-2 RNA by in-house reverse transcription
polymerase chain reaction assay,14 as well as for SARS-CoV-2 anti-
bodies using a native virus antigen ELISA and microneutralisation
assays, both based on the UK prototype strain (GISAID accession
number EPI/ISL/407073), and the samples were subsequently sub-
jected to testing by pseudo-type neutralisation assay and trimeric S
ELISA. Basic donor information including age, gender and virology
testing data were collected.
2.2 | Ethical statement
Signed consent was obtained from each donor at the time of donation.
Donors consent to the NHS blood and transplant holding information
about them, including their health, attendances and donations, and using
their information for the purposes explained in the donor welcome
booklet and data protection leaflet, which donors are asked to read at
the time of donation. This includes using data for the purposes of clinical
audit to assess and improve the service and for research, specifically to
improve our knowledge of the donor population.
2.3 | Infected virus lysate assay
Native virus antigen ELISA was modified from a previously described
MERS-CoV assay.15 Serial dilutions of convalescent plasma samples
were added to microplates containing the bound detergent-extracted
lysates of SARS-CoV-2 (isolate England/02/2020)-infected Vero E6
cells and uninfected cells. The reactivity was determined using a
chemiluminescent substrate labelled secondary antibody. Virus
lysates contain a mixture of viral proteins expressed in Vero E6 cells,
including viral nucleocapsid and S proteins, and these proteins are
presented in the same structure as the native virus infecting the host.
ELISA index value was defined as the difference between infected
and uninfected cell reactivity expressed relative to control calibrator
serum.
2.4 | Microneutralisation assay and neutralising
antibody titre
SARS-CoV-2 (isolate England/02/2020)-specific neutralising antibody
levels were measured using a modification of the World Health Orga-
nization (WHO) influenza microneutralisation methodology.16 Briefly,
the virus was incubated with a serial dilution of convalescent plasma
obtained from recovered patients, after which a suspension of VeroE6
cells was added. After 22 h, cells were fixed, and in-cell SARS-CoV-2
nucleoprotein (NP) expression was determined by ELISA. The virus-
neutralising antibody titre was determined as the serum concentration
that inhibited 50% of SARS-CoV-2 NP expression. All work was
undertaken in a BSL-3 laboratory.
2.5 | Enzyme-linked trimeric S immunosorbent
assay (ELISA–Oxford)
Antibodies to the trimeric S (based on YP009724390.1) protein
were detected by ELISA as previously described, using 2% skimmed
milk in phosphate buffered saline as a blocking agent and alkaline
phosphatase-conjugated anti-human IgG (A95455; Sigma) at
1:10 000 dilution.12 Optical densities (ODs) were measured at
405 nm.
2.6 | Pseudoparticle neutralisation test
A lentivirus-based SARS-CoV-2 pseudovirus particle was constructed
displaying the full S protein on the surface of pseudoparticle as previ-
ously described (accession number: YP009724390.1).12 Neutralising
antibody titres were measured by the reduction in luciferase gene
HARVALA ET AL. 3
expression after 72 h incubation of HEK 293T ACE2-transfected cells
at 37C. The 50% inhibitory dilution (IC50) was defined as the plasma
dilution at which the relative light units (RLUs) were reduced by 50%
compared with the virus control wells after subtraction of the back-
ground RLUs in the groups with cells only.
2.7 | Commercial assays, EUROimmun (IgG) and
Fortress (total antibodies)
EUROimmun assay is based on the S1 protein and Fortress assay on
the RBD of S protein. These assays were performed according to the
manufacturer's recommendation (EUROimmun, PerkinElmer, London,
UK and Fortress Diagnostics, Belfast, Northern Ireland).
2.8 | Statistics
Associations between test assays were compared using Pearson cor-
relation coefficients and the non-parametric Spearman's rank correla-
tion. p-Values were derived using Student's t test for correlations and
Pearson correlation coefficient under the null hypothesis that the cor-
relation was zero. The sensitivity and specificity were calculated to
assess the performance of the different assays in classifying the level
F IGURE 1 Comparison of neutralising antibody titres with reactivity in other assays. Comparison of neutralising antibody titres of the 52 test
samples in the virus neutralisation assay with those of the pseudo-type assay and reactivities in enzyme immunoassay (EIAs). In all graphs,
samples were ordered by virus-neutralising antibody titres. The following assay cut-off values were used: 0.049 for trimeric spike EIA, 1.0 for
Fortress EIA and 1.1 for EUROimmun [Color figure can be viewed at wileyonlinelibrary.com]
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of neutralising antibody titres obtained by microneutralisation assay
using live SARS-CoV-2 virus. Exact binomial confidence intervals were
used to derive confidence intervals.
3 | RESULTS
The initial assessment included samples from 52 recovered patients
who would qualify as donors of convalescent plasma for clinical trials.
They were all males (to avoid the need for additional human leukocyte
antigen and human neutrophil antigen antibody testing that was not
available at the required scale at the time of the study) and at least
28 days from the recovery after laboratory-confirmed SARS-CoV-2
infection. They were sampled during the first 2 weeks of April, imply-
ing that their illness began at the beginning of March. Therefore, they
would all have been hospitalised as a part of the containment strat-
egy. However, no data on the severity of their infection are currently
available. EDTA and serum samples were obtained from each individ-
ual, and a whole-blood donation was collected from 10. All samples
were submitted to Public Health England Colindale, and available
F IGURE 2 Correlations between neutralising
and pseudo-type antibody titres and reactivities in
EIAs. Scatter plots of neutralising antibody titres
of test samples in the virus neutralisation assay
with those of the pseudo-type assay and
reactivities in EIAs. A line of best fit was estimated
by linear regression using log-transformed values
for the virus and pseudo-type neutralising
antibody assays and the EUROimmun EIA.
Correlation coefficients and (two-tailed) p values
were calculated by Spearman non-parametric test
[Color figure can be viewed at
wileyonlinelibrary.com]
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samples were distributed from there to the University of Oxford and
Public Health England Porton Down for further testing. All samples
tested negative for SARS-CoV-2 RNA. Assay specificity (particularly
the rate of false reactives) has not been included in this analysis.
Neutralising antibodies were detected by microneutralisation
assay in 43 of 52 tested samples using a cut-off titre 1:20; the
highest detectable titre was 1:4096 (Figure 1). In other assays,
SARS-CoV-2 antibodies were detected in most samples tested by
pseudo-type assay (47/51), lysate ELISA (47/50) and EUROimmun
(47/50) and in all samples by trimeric S ELISA (51/51) and Fortress
total antibody ELISA (50/50). Based on these initial observations, all
assays demonstrated good sensitivity for detecting antibodies in the
study subjects 28 days after their recovery. For most assays, quanti-
tative measures of serological reactivity (IC50 in the pseudo-type
assay, ODs or signal to cut-off ratios (S/CO)) suggested a trend
with neutralising antibody titres based on the live virus
microneutralisation assay (Figure 1).
We have further assessed the correlation between neutralising
antibody titre and serological reactivities in different ELISA platforms
(Figure 2) where Pearson correlation coefficients and the non-
parametric Spearman's Rank correlation tests were performed. The
Pearson correlation tests were used for a linear association between
variables (using log-transformed values for the neutralisation, pseudo-
type and EUROimmun assays; R2 values), whereas Spearman's coeffi-
cient determined correlations in ranking irrespective of magnitude. A
further comprehensive pairwise comparison between all assays is pro-
vided in Figure S1.
The strongest correlation was observed between neutralising
antibody titres and reactivity in the EUROimmun IgG ELISA
(Spearman's rank correlation: 0.88; p < 0.0001, n = 48). Correlations
were also observed between neutralising antibody titres with IC50
values in the pseudo-type assay (Spearman's rank correlation: 0.82;
p < 0.0001, n = 51) and trimeric S ELISA (Spearman's rank correlation:
0.76; p < 0.0001, n = 51).
We selected a neutralising antibody titre of 1:100 as a likely ther-
apeutic threshold for plasma donation selection (see discussion) and
determined the best corresponding cut-off value in the EUROimmun
ELISA by ROC analysis (Table 1; Figure 3). A total of 22 of 48 samples
with a EUROimmun result had a neutralising antibody titre higher
than or equal to 1:100 and hence contributed to the sensitivity calcu-
lations. Similarly, the remaining 26 samples with neutralising antibody
titre below 1:100 contributed to the specificity calculations. Five
potential cut-off values in the EUROimmun ELISA (S/CO values
between 6.37 and 10) were investigated for sensitivity and specificity;
a value of 9.1 correctly identified 65% of donations (14/22) above the
1:100 neutralising antibody threshold, whereas all donations below
this neutralising antibody threshold were identified correctly using
this value (26/26). In contrast, the pseudo-type assay was unable to
identify 50% or more donations >1:100 without false identification.
4 | DISCUSSION
Here, we have described the first evaluation of the relationship
between neutralising antibody titres and measures of antibodies to
SARS-CoV-2 proteins in a variety of assays. These data can guide the
selection of units of convalescent plasma for clinical use and for
randomised clinical trials.
TABLE 1 Threshold values for optimal sensitivity and specificity
of EUROimmun and pseudo-type neutralisation assays by ROC
analysis
Cut-off value Sensitivity (95% CI) Specificity (95% CI)
EUROimmun S/CO
6.37 0.95 (0.76, 1.00) 0.89 (0.98, 0.77)
6.64 0.76 (0.53, 0.92) 0.93 (1.00, 0.83)
8.19 0.68 (0.48, 0.83) 0.96 (0.99, 0.85)
9.1a 0.65 (0.45, 0.81) 1.00 (1.00, 0.92)
10 0.52 (0.30, 0.74) 1.00 (1.00, 1.00)
Pseudo-type neut. titre
573 0.86 (0.64, 0.97) 0.90 (0.98, 0.73)
770 0.48 (0.26, 0.70) 0.93 (0.99, 0.78)
Note: These calculations are based on 48 samples, from which 22 had
neutralising antibody levels of or over 1:100, and the remaining 26 were
below 1:100.
aOptimal value selected for donation selection shown in bold.
F IGURE 3 ROC analysis of serology assays predicting virus-
neutralising antibody titres of ≥1/100. OC curves for the pseudo-
type, virus lysate and three EIAs to correctly identify samples with
neutralising antibody titres of 1:100 and over in the virus
neutralisation assay. A total of 48 samples were included in these
calculations (22 with neutralising antibody levels of or over 1:100 and
the remaining 26 below 1:100). Areas under the curve for each assay
are shown in colour-coded boxes [Color figure can be viewed at
wileyonlinelibrary.com]
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Our initial observation of convalescent plasma donors sampled at
least 28 days after recovery from a laboratory-confirmed SARS-
CoV-2 infection showed that all of them demonstrated serological
evidence of past SARS-CoV-2 infection in one or more assays,
whereas the neutralising antibody levels detected by
microneutralisation assay varied from low (1:20) to high (1:4096;
Figure 1). Furthermore, approximately 43% of donor samples showed
neutralising antibody titres greater than 1:100. These neutralising
antibody titres obtained by the microneutralisation assay correlated
with values obtained by pseudovirus assay; a titre of 1:100 cor-
responded to 1:300 calculated based on luminescence reading.
Although the pseudo-type assay can be automated and does not
require working with the live virus in a biosafety level 3 laboratory, it
is still time-consuming compared to the ELISA-based assay and
requires the use of live cells and BSL-2 facilities that are often lacking
from blood donation screening and reference laboratories.
In a previous study, most convalescent plasma donors with previ-
ous COVID-19 infection showed high neutralising antibody titres of
at least 1:160 determined by the plaque reduction neutralisation test
(PRNT; 39/40). For CPT, only donations with antibody titres above
1:640 were used.5 In a separate study, donations with a neutralising
antibody titre equal or higher than 1:80 based on the
microneutralisation test were used successfully.6 It is important to
note that antibody titres obtained by different assays may not be
comparable; based on previous data on SARS-CoV-2, neutralising
antibody titres obtained by PRNT were approximately four-fold higher
than those obtained by a cytopathic effect (CPE)-based
microneutralisation assay.17 CPE refers to structural changes in host
cell, caused by virus invasions. Further comparative work is required
to determine how the neutralising antibody level obtained by our
microneutralisation assays compares with the PRNT titres and also
with assays performed outside the United Kingdom. The future avail-
ability of WHO international standards will facilitate such compari-
sons; this is anticipated to be available in December 2020.
A minimum neutralising antibody titre in convalescent plasma
needs to be determined before plasma is supplied for clinical trials. This
needs to be balanced with the difficulty of collecting a required num-
ber of such components and providing a sufficient dose of antibodies
to potentially be effective. For the planned trial, the use of plasma with
a too-low cut-off may prevent or prolong a clear demonstration of effi-
cacy; conversely, a too high cut-off may prevent a sufficient supply of
plasma to fulfil trial needs. The chosen neutralising antibody level,
1:100, was selected as a pragmatic cut-off that enables an estimated
40% of collected plasma to be used. The actual dose of neutralising
antibody given to patients also depends on the number of units given,
and giving two units from different donors may substantially increase
the mean dose to more than 1:300. Although considered potentially
effective, how this level obtained by the microneutralisation assay
compares with PRNT titres used in previous studies requires further
work. This cut-off will be reviewed after a larger number of samples
have been analysed to see if supply is meeting demand.
In order to support the scaling up the convalescent plasma pro-
duction, it is important to identify a suitable high-throughput ELISA
assay that can be used to estimate the neutralising antibody levels in
convalescent plasma samples and thus could determine which dona-
tions are offered for clinical use. Serological reactivity in both the
EUROimmun SARS-CoV-2 IgG ELISA and the trimeric S SARS-CoV-2
ELISA showed a strong correlation with neutralising antibodies
obtained either by microneutralisation test or by pseudo-type assay.
Although the EUROimmun assay has been shown to lack sensitivity
for samples collected from patients with recent infection,18 we have
shown that it could be used to identify donations containing high
levels of neutralising antibodies with a good level of specificity. By
selecting an S/CO cut-off value of 9.1, the assay would only identify
units if the neutralising antibody titre was 1:100 or higher. This is con-
sistent with a previous finding where plasma with high titres of
neutralising SARS-CoV-2 antibodies also showed higher titres of RBD,
S domain 1 or 2 and specific binding antibodies.8 Trimeric S ELISA falls
within the RBD domain located in the S domain 1, whereas
EUROimmun targets S domain 1. However, it is important to note that
this is based on testing a preselected cohort of individuals at least
28 days after recovery from a previous laboratory-confirmed SARS-
CoV-2 infection. The evaluation should be repeated if these criteria
are changed or if the screening of native blood donor populations
without a prior history of SARS-CoV-2 infection is considered.
As only a small number of samples from preselected convalescent
plasma donors have been tested so far, which is a limitation of this
study, we propose that several assay formats should be employed in a
larger group of donors to validate these findings before the scaling up
can be finalised. For practical and economic reasons, we decided to
extend neutralising antibody testing up to 300 samples and then final-
ise analysis. Nevertheless, the results provide guidance for the many
convalescent plasma programmes in progress around the world.
Neutralising antibody levels are partly dependent on the timing of
collection relative to the recovery from infection. Seroconversion fol-
lowing SARS-CoV-2 infection has been observed between 8 and
21 days after the onset of symptoms,9,19-21 and higher levels of anti-
bodies have been determined in plasma collected at least 14 days
after the symptom resolution.5 It is likely that the antibody maturation
continues for longer as demonstrated for other viruses, and hence,
the collection point of 28 days after recovery has been chosen here.
This maximises the chances of collecting the most clinically effective
donations. However, it is still unclear how long neutralising antibody
levels are maintained, and hence, repeat testing will be performed at
every donation.
Higher neutralising SARS-CoV-2 antibody levels have been asso-
ciated with older age and a worse clinical outcome,8,21 although good
neutralising antibody levels have also been measured in individual
patients with milder infections.22,23 The monitoring of neutralising
antibody levels in different patient groups (including females not
included in this study) and over time is required and will inform future
screening strategies.
In conclusion, here, we have demonstrated a correlation between
the neutralising antibody level and antibody reactivity measured by
ELISA, which will allow scaling up of the convalescent plasma produc-
tion. However, continuous monitoring of assay performance, antibody
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decay and adaptation of selection strategies will be required in order
to deliver the best clinical outcomes for patients receiving neutralising
SARS-CoV-2 antibodies through CPT.
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